Compare Twist Bioscience Corp (TWST) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs State Street PDR S&P Retail ETF — how do they compare? Twist Bioscience Corp trades at $157 (market cap $10.08B), while State Street PDR S&P Retail ETF trades at $86.52 (market cap $389.66M). The key difference: Twist Bioscience Corp is far larger — about 25.9× State Street PDR S&P Retail ETF's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, State Street PDR S&P Retail ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and State Street PDR S&P Retail ETF for 44 Days on average.
| TWST | XRT | |
|---|---|---|
Market Cap | $10.08B | $389.66M |
Volume | 4,229,037 | 4,275,820 |
Sector | Health | Broad Market / Factor |
52-Week High | $205.00 | $92.35 |
52-Week Low | $25.45 | $77.28 |
Typical Hold Time | 27 Days | 44 Days |
Enterprise Value | $10.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
XRT, the SPDR S&P Retail ETF, trades at $82.91, down 0.05% on the day, with a bearish technical signal from moving averages. The ETF faces headwinds from higher interest rates and inflation pressuring consumer spending, as reflected in mixed retail sales data. Recent news highlights holiday sales projections exceeding $1 trillion but also notes analyst expectations of underperformance versus the S&P 500 into 2027.
The outlook for XRT is cautious due to macroeconomic pressures on retail, though potential Fed easing could offer relief. Risks include consumer sentiment volatility and competitive shifts. Analyst sentiment is neutral to bearish, with institutional interest shown via options activity but no strong bullish consensus for near-term outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
